Selective protection of nonmalignant cells by a novel cell surface glycopeptide.

A novel glycopeptide inhibitor of cell division, isolated from bovine cerebral cortex cell surfaces, was shown to selectively protect nonmalignant cells from the cytoxic action of 5-bromo-2-deoxyuridine (5-BrdUrd). When mouse LM-22 cells (nonmalignant and devoid of gangliosides) were preincubated with GM1 ganglioside (3.0 micrograms/ml), the cell surface glycopeptide inhibitor effectively arrested cell division. In contrast to LM-22 cells, transformed mouse fibrosarcoma (No. 1316) cells were insensitive to the glycopeptide inhibitor whether or not they were preincubated with GM1 ganglioside. Mixed cultures of LM-22 cells preincubated with GM1 ganglioside and 1316 fibrosarcoma cells at an approximate ratio of 1:1 were established. Since LM-22 cells are resistant and 1316 fibrosarcoma cells are sensitive to 3.0 mM ouabain, the identity of surviving cells following BrdUrd treatment could easily be determined. Three hr after the establishment of the mixed cell population, 250 ng protein per ml of the purified bovine glycopeptide inhibitor was added to selectively arrest the mitosis of the LM-22 cells. After an additional 3 hr of incubation, 5-BrdUrd was added to a final concentration of 5.0 mM. Twelve hr later, cells were serially diluted and seeded into duplicate plates with and without 3.0 mM ouabain. LM-22 cells were effectively protected from the cytotoxic action of 5-BrdUrd (92 to 94% survival) while the majority of the 1316 fibrosarcoma cells were killed (21 to 30% survival). The selective protection of LM-22 cells was shown to be independent of differences in plating efficiency, cytotoxicity of 5-BrdUrd in the absence of the glycopeptide inhibitor, and the generation time of the two cell lines.

High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracyclic imidazoquinoxalines.

A series of tetracyclic imidazoquinoxaline analogs was developed which constrain the carbonyl group of the partial agonist 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(dimethylamino)carbonyl] - 4,5-dihydroimidazo[1,5-alpha]quinoxaline (2, U-91571) away from the benzene ring. These analogs orient the carbonyl group in the opposite direction of the previously reported full agonist 1-(5- cyclopropyl-1,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazo[1,5- alpha]pyrrolo [2,1-c]quinoxalin-10(11H)-one (3, U-89267). A number of approaches were utilized to form the "bottom" ring of this tetracyclic ring system including intramolecular cyclizations promoted by Lewis acids or base, as well as metal-carbenoid conditions. The size and substitution pattern of the additional ring was widely varied. Analogs within this series had high affinity for the benzodiazepine receptor on the alpha-aminobutyric acid A chloride ion channel complex. From TBPS shift and Cl- current assays, the in vitro efficacy of compounds within this class ranged from antagonists to partial agonists with only 18a identified as a full agonist. Additionally, several analogs were quite potent at antagonizing metrazole-induced seizures indicating possible anticonvulsant or anxiolytic activity. Unlike 3, analogs in this series did not have high affinity for the diazepam insensitive alpha 6 beta 2 delta 2 subtype. These results suggest that either constraining the carbonyl group away from the benzene ring or the greater planarity that results from the additional cyclic structure provides analogs with partial agonist properties and prevents effective interaction with the alpha 6 beta 2 delta 2 subtype.

Cultural differences in reactions to patient behaviour: a comparison of Swedish and Australian health professionals.

Scott hypothesised that there are national differences in the theories held by health professionals regarding rehabilitation. Thus they have different perceptions of and reactions to patient behaviours. This was tested by comparing the reactions of female physiotherapists, occupational therapists and nurses in Sweden (N = 51) and Australia (N = 83) to behaviours of patients belonging to six diagnostic groups. It was predicted that national differences would be influenced by Australians' endorsement of a more psycho-social model of health care and Swedes' stronger beliefs in personal responsibility for health. Questionnaires containing case histories of the six patients and transcripts of interviews in which they expressed either depression, optimism, dependence, independence, self-blame or denial of blame for their illnesses were distributed to subjects. Case histories and interview transcripts were combined differently in six forms of the questionnaire. Subjects rated their impressions and evaluations of each patient on 14 Likert type scales and answered the question, "If the patient had said this to you how would you have reacted?" Subjects completed the Health Locus of Control Scale on which Swedes proved to have significantly stronger beliefs regarding personal responsibility for health. Highly significant differences were found in discriminant analyses of reactions to the six behaviours. Australians were more likely to perceive patients as dependent, depressed and poorly adjusted. They responded verbally to patients' feelings, recommended counselling and liked patients more. Swedes were more likely to react with specific treatments and technical aids. Swedes regarded patients who were dependent or who did not blame themselves as having poorer prognoses. Few differences occurred in ratings of the typicality of patients' behaviours or the degree of patients' acceptance or coping. The findings have particular relevance to multi-cultural nations. Bias may have occurred in the results because subjects represented only 40% of those sent the questionnaires.

Purification of lincosaminide O-nucleotidyltransferase from Streptomyces coelicolor Müller.

An enzyme (lincosaminide O-nucleotidyltransferase) that catalyzes 3-(5'-ribonucleotidylation) of pirlimycin and several other lincosaminide antibodies has been purified approximately 35-fold from cell-free extracts of Streptomyces coelicolor Müller NRRL 3532 (UC 5240). The crude enzyme was prepared using lysozyme and was treated with MnCl2 and (NH4)2SO4. Final purification was achieved by anion exchange chromatography. The pirlimycin reaction product was verified as being pirlimycin-3-(5'-adenylate) by NMR spectroscopy and MS. As a result of purification, this lincosaminide nucleotidylating and inactivating enzyme was separated from the macrolide phosphorylating enzyme also present in the cell-free extract.

Intra-aortic balloon pump: a perspective.

The mortality from acute myocardial infarction has declined 14-18 percent since the advent of coronary care units. This decline has been attributed to the early detection and prophylactic treatment of cardiac arrhythmias and conduction disturbances. Infarction complicated by congestive heart failure and cardiogenic shock accounts for major residual mortality. Available evidence in man have shown reversal of cardiogenic shock with the use of mechanical circulatory assistance via the intra-aortic balloon pump (IABP). Expanded IABP use now includes unstable angina refractory to medical therapy and post infarction ischemic pain. Future roles of IABP include its earlier use in the management of complicated myocardial infarction, as well as a modality useful in reducing myocardial infarction size.

Management of cervical dysplasia in pregnancy.

Nurse practitioners who provide women's health care play an important role in the screening and evaluation of cervical dysplasia. The pregnant woman who presents for prenatal care provides an excellent opportunity for cervical cancer screening. However, the evaluation and management of cervical dysplasia during pregnancy is complicated by numerous factors, including concern for the fetus and hormonal changes in the pelvic structures. The pathophysiology, evaluation and management of cervical dysplasia during pregnancy are presented.

Erythrocyte-neutrophil interactions: formation of leukotriene B4 by transcellular biosynthesis.

Studies on the mechanism of leukotriene B4 biosynthesis in suspensions composed of neutrophils plus erythrocytes indicate that human erythrocytes convert neutrophil-derived leukotriene A4 into leukotriene B4. Leukotriene B4 formation by neutrophils in the presence of erythrocytes exceeded that from corresponding suspensions of neutrophils alone. The increase was proportional to the erythrocyte content of the suspension. The erythrocyte-dependent increase in leukotriene B4 biosynthesis did not equal the arithmetic sum of calcium ionophore-dependent biosynthesis by neutrophils plus calcium ionophore-dependent biosynthesis by erythrocytes, since erythrocytes produced no leukotriene B4 upon incubation with ionophore A23187. Erythrocytes did not stimulate 5-lipoxygenase activity within neutrophils, since the erythrocyte effect was confined to enzymatic hydration: leukotriene B4 increased coincident with decreased formation of 5,12-dihydroxyicosatetraenoic acids derived from nonenzymatic hydration. Biosynthesis of leukotriene B4 within the erythrocyte, from neutrophil-derived leukotriene A4, was established by comparing the effect of normal erythrocytes with erythrocytes containing a leukotriene A4 hydrolase that was inactivated by the substrate. In the latter case, leukotriene B4 formation increased by only 30-40%; in the former case, it increased by 100-200%. Transcellular biosynthesis of leukotriene B4 from erythrocyte-neutrophil interactions explains the paradoxical presence of leukotriene A4 hydrolase within erythrocytes, a cell incapable of synthesizing leukotriene A4; affords a mechanism to overcome rate limitations or "suicide inactivation" of leukotriene A4 hydrolase in neutrophils; exploits a cryptic capacity within erythrocytes, provisionally dormant cells in terms of icosanoid biosynthesis; indicates that the biosynthetic capacity of cell combinations is not necessarily equivalent to the sum of their separate capacities.

A cryptic plasmid from Pasteurella multocida has a predicted protein nearly identical to a transport protein from Actinobacillus actinomycetemcomitans.

Several plasmids from Pasteurella multocida have been shown to carry antibiotic resistance genes but no other genes possibly related to the organism's pathogenesis. We report here that sequence from the plasmid pLEM from a fowl isolate of P. multocida, strain 1059, contained one open reading frame that had significant identity with a predicted protein from pVT745, a plasmid that was isolated from a human oral isolate of Actinobacillus actinomycetemcomitans. This predicted protein had significant homology at the amino acid level to cation transport proteins.

Neuroblastoma cell membranes: specificity for cell fusion mediated by a temperature-sensitive mutant of vesicular stomatitis virus.

Temperature-sensitive mutant G31 of vesicular stomatitis virus induces mouse neuroblastoma N-18 cells to fuse during infections that are nonpermissive for virus replication, but BHK-21 cells do not undergo the viral glycoprotein-mediated cell fusion. The viral glycoprotein was expressed at the cell surface of both N-18 and BHK-21 cells; therefore, the host cell specificity did not stem from an absence of the viral glycoprotein at the surface of BHK-21 cells. Cell fusion readily occurred between infected and uninfected N-18 cells in mixed cultures, demonstrating that the viral glycoprotein was interacting with an uninfected cell for the initial cell-cell interaction of the cell fusion. Mixing infected BHK-21 cells with uninfected N-18 cells resulted in cell fusion initiated by BHK-21 cell-synthesized viral glycoprotein, but 88% of the nuclei in polykaryocytes were N-18 nuclei. The N-18 cell fusion specificity was readily apparent when infected N-18 cells were mixed with uninfected BHK-21 cells; 98% of the nuclei in polykaryocytes were N-18 nuclei. Similar results also were obtained with mixed cultures of N-18 cells and primary astroglial cells. Thus, the viral glycoprotein synthesized in any of the cell types could initiate cell fusion, but the properties of plasma membranes of neuroblastoma cells appeared to be much more suitable for cell-cell fusion.

Two signal transduction pathways mediate interleukin-1 receptor expression in Balb/c3T3 fibroblasts.

Our previous studies showed that platelet-derived growth factor (PDGF) modulated interleukin-1 (IL-1) activity and IL-1 binding to Balb/c3T3 fibroblasts (Bonin, P. D., and Singh, J. P. (1988) J. Biol. Chem. 263, 11052-11055). Subsequent studies have demonstrated an action of PDGF at the level of IL-1 receptor (IL-1R) gene expression. PDGF treatment of Balb/c3T3 cells produces a 10-20-fold stimulation of mRNA for IL-1 receptor. Investigation of the signal transduction pathways shows that activation of either the protein kinase C pathway or the cAMP-mediated pathway leads to the stimulation of IL-1 receptor expression in Balb/c3T3 cells. Treatment of Balb/c3T3 cells with phorbol 12-myristate 13-acetate (PMA), a known activator of protein kinase C, produced an increased 125I-IL-1 binding to cells and stimulation of IL-1R mRNA. Staurosporine, an inhibitor of protein kinase C, blocked the induction of IL-1 binding by PDGF or PMA. Down-regulation of protein kinase C by pretreatment with PMA reduced the subsequent stimulation by PDGF. Chronic treatment with PMA, however, did not produce a complete inhibition of PDGF effect on IL-1R. Further studies showed that the agents that stimulate cAMP accumulation (isobutyl methylxanthine, dibutyryl), directly stimulate adenylate cyclase (forskolin), or activate G protein (choleragen) stimulated 125I-IL-1 binding and IL-1R mRNA accumulation in Balb/c3T3 cells. These studies suggest that potentially two signal transduction pathways mediate IL-1 receptor expression in Balb/c3T3 fibroblasts. Evidence is presented that suggests that stimulation of IL-1R through these two pathways (PMA/PDGF-stimulated and cAMP-stimulated) occurs independent of each other.

Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry.

Certain epoxyeicosatrienoic acids (EETs) that were not cyclooxygenase substrates were effective cyclooxygenase inhibitors. Both (+/-)-14,15-cis-EET and (+/-)-8,9-cis-EET inhibited purified enzyme at concentrations from 1 to 50 microM; (+/-)-11,12-cis-EET was ineffective at concentrations below 100 microM. For the case of 14,15-cis-EET, only the (14R,15S)-stereoisomer was active. Other isomers including (14S,15R)-cis-EET, (14R,15R)-trans-EET, (14S,15S)-trans-EET, and the erythro and threo vicinal 14,15-diols were inactive. In addition to their effects on isolated enzyme preparations, cyclooxygenase activity in platelet suspensions, reflected by thromboxane B2 formation, was also inhibited by (14R,15S)-cis-EET and (+/-)-8,9-cis-EET but not by the other isomers. Thus potency and stereospecificity requirements were maintained for cyclooxygenase within intact platelets. Unlike the stereospecific inhibition of the cyclooxygenase enzyme, platelet aggregation induced by arachidonic acid was inhibited by all EET isomers at concentrations from 1 to 10 microM with no evident stereospecificity. Inhibition of aggregation was not uniformly associated with inhibition of thromboxane B2 formation; ordinarily, these two parameters correlate closely. This dissociation was not maintained for another biochemical process involved in platelet activation. For instance, there was a uniform correlation between inhibition of phosphorylation of a 40-kDa platelet protein and inhibition of aggregation. Our results suggest that effects of EET may originate from either stereospecific or nonspecific mechanisms. Definition of such mechanisms may be important to appreciate any physiological relevance of these substances.

FKBP-12 is not an inhibitor of protein kinase C.

It was recently noted that the amino acid sequence of FK506 binding protein (FKBP-12) is nearly identical to that of an endogenous inhibitor of protein kinase C, PKCI-2. To follow up on this observation, we have tested the hypothesis that FKBP-12 is an inhibitor of PKC. The kinase activity of rat brain protein kinase C (PKC) was not inhibited by the presence of up to 700 micrograms recombinant human FKBP-12 per ml, in either the presence or absence of FK506. FKBP-12 also did not affect PMA-induced phosphorylation of an endogenous PKC substrate, an 80 kDa protein, in permeabilized cells. To test whether FKBP-12 could account for endogenous PKC inhibitory activity in cells, Jurkat cell lysate was chromatographed on an anion exchange column. A peak of PKC inhibitory activity was eluted at approximately 200 mM NaCl. As shown by both Western blots and FK506 binding activity, FKBP-12 was eluted only in the flow-through and wash fractions. These results demonstrate that FKBP-12 is clearly distinct from endogenous PKC inhibitory activity.

Spectral characterization of environment-sensitive adducts of interleukin-1 beta.

We have determined the fluorescence properties of two covalently attached acrylodan derivatives of recombinant human interleukin-1 beta, namely the Cys-8 and Lys-103 adducts. The emission and excitation maxima indicated the presence of two operationally distinct conformers for each probe. The iodide quenching and the kinetics of fluorescence changes associated with guanidinium chloride-induced denaturation show that each covalent adduct exists both in hydrated and dehydrated environments. Furthermore, fluorescence changes associated with the binding of the adducts to a recombinant soluble murine receptor indicated that only the conformers with the label in the hydrophobic environment are competent toward the soluble murine interleukin receptor and that the hydrated and dehydrated conformers are in a dynamic equilibrium on the time scale of the binding experiments.